Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

Now Viewing

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.

Pipe addresses the critical issue of optimizing hemophilia treatment schedules and minimizing medication hoarding. The focus is on ensuring timely and infrequent reorders of prophylactic medications for patients. With a particular emphasis on emicizumab, given its extended dosing intervals, pharmacies often dispense 1 to 2 months' worth, effectively regulating the vial quantities at home. Unlike the factor replacement therapy era, where frequent dispensing was needed, emicizumab's lower intensity prophylaxis reduces the necessity for regular insurance doses. Pipe emphasizes the importance of communication among patients, health care providers, and pharmacies to match inventory with utilization, avoiding wastage and expiration. The discussion also delves into challenges with emicizumab vial sizes, highlighting the need for more options to accommodate individual patient weights. While adherence remains a consideration, the consequences of nonadherence with emicizumab are comparatively minimized, providing reassurance to patients. The interview underscores evolving strategies to optimize treatment efficiency, enhance patient adherence, and navigate the unique considerations associated with both factor replacement and emicizumab therapies in hemophilia care.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.